Recently, the 2020 National Pharmacy Week, China Pharmaceutical Industry Top 100 Annual Conference, and China Pharmaceutical Internet Economy Annual Conference were held in Kunming. During the conference, the award ceremony of the “2019 China Pharmaceutical Industry Top 100 Series” was held, and the five major The sub-list and the 260 selected companies demonstrate the professionalism and influence of China's top 100 pharmaceutical companies. Yiling Pharmaceutical was selected as the TOP10 sub-list of "Top 100 Chinese Medicine Companies".
Yiling Pharmaceutical was awarded the top 10 of Chinese traditional Chinese medicine companies in 2019
It is reported that the list of the top 100 Chinese pharmaceutical industry has been held for more than ten years since its establishment in 2006, and it has become one of the most watched and authoritative pharmaceutical rankings in China . The selection focuses on the innovation driving force and professional promotion power of pharmaceutical industry enterprises, so as to accurately reflect the R&D and production strength and market promotion capabilities of the participating companies. The selection has received full attention and active participation from a large number of professional research institutions, experts, scholars, and entrepreneurs, and has been highly praised.
In recent years, Yiling Pharmaceutical has stepped into the fast lane of development and has been ranked among the top 500 Chinese listed companies and the top 20 listed Chinese pharmaceutical companies with major influence. The performance forecast released by Yiling Pharmaceutical recently showed that the company's net profit in the first half of this year increased by more than 50% year-on-year, surpassing the entire year of last year.
Yiling Pharmaceutical Co., Ltd. drives the industrialization of traditional Chinese medicine with collateral disease theory innovation, uses modern high-tech research and development, and produces scientific and technological traditional Chinese medicine, covering major diseases such as cardiovascular and cerebrovascular diseases, respiratory diseases, tumors, diabetes, nerves, and urinary system diseases. , The product layout is complete and the echelon is reasonable. Currently, Yiling Pharmaceutical has 11 patented Chinese medicine varieties, of which 7 are listed in the National Medical Insurance Catalogue, and 5 are national basic medicines, and a series of patented drug clusters at different stages of research and development have been formed. Among them, the annual sales of Lianhua Qingwen, Tongxinluo, and Shensongyangxin Capsules are over 1 billion yuan. In January this year, Hebei Yiling Medical Research Institute, a subsidiary of Yiling Pharmaceuticals, as the first main research unit, won the first prize of the 2019 National Science and Technology Progress Award. The milestone breakthrough in the field of traditional Chinese medicine has created a new model of innovation and transformation of traditional Chinese medicine technology, with significant social and economic benefits.
Under the background of the vigorous promotion of the current national policy, Yiling Pharmaceutical will further exert its advantages in R&D and production, inherit the essence, maintain integrity and innovation, promote the revitalization and development of Chinese medicine, and accelerate the modernization, industrialization and internationalization of Chinese medicine. Development contributes to Ling power.
